Real-Time Monitoring and Point-of-Care Testing: A Review of the Current Landscape of PrEP Adherence Monitoring

References

• Centers for Disease Control and Prevention. HIV in the United States and Dependent Areas. CDC; 2020.
   Google Scholar
• Centers for Disease Control and Prevention. HIV prevention pill not reaching most Americans who could benefit – especially people of color. 2018.
   Google Scholar
• US Food and Drug Administration. FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic. 2019
   Google Scholar
• IDSE Infectious Disease Special Edition. FDA Advisory Committee Endorses Descovy for PrEP for MSM. 2019.
   Google Scholar
• Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-resistant HIV-1 infection despite preexposure prophylaxis. N Engl J Med. 2017;376:501–502. doi:10.1056/NEJMc1611639
   PubMed Web of Science ®Google Scholar
• Markowitz M, Grossman H, Anderson PL, et al. Newly acquired infection with multidrug-resistant HIV-1 in a patient adherent to preexposure prophylaxis. J Acquir Immune Defic Syndr. 2017;76:e104–e6. doi:10.1097/QAI.0000000000001534
   Web of Science ®Google Scholar
• Hoornenborg E, Prins M, Achterbergh RCA, et al. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Lancet HIV. 2017;4:e522–e8. doi:10.1016/S2352-3018(17)30132-7
   Web of Science ®Google Scholar
• Eaton LA, Matthews DD, Bukowski LA, et al. Elevated HIV prevalence and correlates of PrEP use among a community sample of black men who have sex with men. J Acquir Immune Defic Syndr. 2018;79:339–346. doi:10.1097/QAI.0000000000001822
   PubMed Web of Science ®Google Scholar
• Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS. 2012;7:542–548. doi:10.1097/COH.0b013e3283582d4a
   Web of Science ®Google Scholar
• van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS (London, England). 2012;26:F13–F19. doi:10.1097/QAD.0b013e3283522272
   PubMed Web of Science ®Google Scholar
• Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820–829. doi:10.1016/S1473-3099(14)70847-3
   PubMed Web of Science ®Google Scholar
• Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 Infection. N Engl J Med. 2015;373:2237–2246. doi:10.1056/NEJMoa1506273
   PubMed Web of Science ®Google Scholar
• Landovitz RJ, Beymer M, Kofron R, et al. Plasma tenofovir levels to support adherence to TDF/FTC preexposure prophylaxis for HIV prevention in MSM in Los Angeles, California. J Acquir Immune Defic Syndr. 2017;76:501–511. doi:10.1097/QAI.0000000000001538
   Web of Science ®Google Scholar
• Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–422. doi:10.1056/NEJMoa1202614
   PubMed Web of Science ®Google Scholar
• Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–518. doi:10.1056/NEJMoa1402269
   PubMed Web of Science ®Google Scholar
• Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–2599. doi:10.1056/NEJMoa1011205
   PubMed Web of Science ®Google Scholar
• HPTN Trial Network. HPTN 083 Study Summary. 2020.
   Google Scholar
• HPTN Trial Network. HPTN 084 Study Summary. 2020.
   Google Scholar
• Hannaford A, Lipshie-Williams M, Starrels JL, et al. The use of online posts to identify barriers to and facilitators of HIV Pre-exposure Prophylaxis (PrEP) among men who have sex with men: a comparison to a systematic review of the peer-reviewed literature. AIDS Behav. 2018;22:1080–1095. doi:10.1007/s10461-017-2011-3
   PubMed Web of Science ®Google Scholar
• Drain PK, Bardon AR, Simoni JM, et al. Point-of-care and near real-time testing for antiretroviral adherence monitoring to HIV treatment and prevention. Curr HIV/AIDS Rep. 2020;17:487–498. doi:10.1007/s11904-020-00512-3
   Web of Science ®Google Scholar
• Bardon AR, Simoni JM, Layman LM, Stekler JD, Drain PK. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers. AIDS Res Ther. 2020;17:50. doi:10.1186/s12981-020-00308-w
   Web of Science ®Google Scholar
• Spinelli MA, Glidden DV, Anderson PL, et al. Brief report: short-term adherence marker to PrEP predicts future nonretention in a large PrEP demo project: implications for point-of-care adherence testing. J Acquir Immune Defic Syndr. 2019;81:158–162. doi:10.1097/QAI.0000000000002005
   Web of Science ®Google Scholar
• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (New York, NY). 2010;329:1168–1174.
   Google Scholar
• Baxi SM, Liu A, Bacchetti P, et al. Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr. 2015;68:13–20. doi:10.1097/QAI.0000000000000386
   Web of Science ®Google Scholar
• Koss CA, Hosek SG, Bacchetti P, et al. Comparison of measures of adherence to human immunodeficiency virus preexposure prophylaxis among adolescent and young men who have sex with men in the United States. Clin Infect Dis. 2018;66:213–219. doi:10.1093/cid/cix755
   PubMed Web of Science ®Google Scholar
• Wilson IB, Lee Y, Michaud J, Fowler FJ, Rogers WH. Validation of a new three-item self-report measure for medication adherence. AIDS Behav. 2016;20:2700–2708. doi:10.1007/s10461-016-1406-x
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016;32:32–43. doi:10.1089/aid.2015.0182
   PubMed Web of Science ®Google Scholar
• Krumpal I. Determinants of social desirability bias in sensitive surveys: a literature review. Qual Quant. 2013;47:2025–2047. doi:10.1007/s11135-011-9640-9
   Web of Science ®Google Scholar
• Messou E, Kouakou M, Gabillard D, et al. Medication possession ratio: predicting and decreasing loss to follow-up in antiretroviral treatment programs in Côte d’Ivoire. J Acquir Immune Defic Syndr. 2011;57(Suppl 1):S34–S39. doi:10.1097/QAI.0b013e3182208003
   Web of Science ®Google Scholar
• Sangeda RZ, Mosha F, Prosperi M, et al. Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health. 2014;14:1035. doi:10.1186/1471-2458-14-1035
   PubMed Web of Science ®Google Scholar
• Bell KM, Haberer JE. Actionable adherence monitoring: technological methods to monitor and support adherence to antiretroviral therapy. Curr HIV/AIDS Rep. 2018;15:388–396. doi:10.1007/s11904-018-0413-0
   Web of Science ®Google Scholar
• Haberer JE, Bangsberg DR, Baeten JM, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS (London, England). 2015;29:1277–1285. doi:10.1097/QAD.0000000000000647
   PubMed Web of Science ®Google Scholar
• Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–434. doi:10.1056/NEJMoa1110711
   PubMed Web of Science ®Google Scholar
• Okatch H, Beiter K, Eby J, et al. Brief report: apparent antiretroviral overadherence by pill count is associated with HIV treatment failure in adolescents. J Acquir Immune Defic Syndr. 2016;72:542–545. doi:10.1097/QAI.0000000000000994
   Web of Science ®Google Scholar
• Liu X, Lewis JJ, Zhang H, et al. Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: a cluster-randomised trial. PLoS Med. 2015;12:e1001876. doi:10.1371/journal.pmed.1001876
   PubMed Web of Science ®Google Scholar
• Haberer JE, Musiimenta A, Atukunda EC, et al. Short message service (SMS) reminders and real-time adherence monitoring improve antiretroviral therapy adherence in rural Uganda. AIDS (London, England). 2016;30:1295–1300. doi:10.1097/QAD.0000000000001021
   PubMed Web of Science ®Google Scholar
• Abbasi J. HIV preexposure prophylaxis “smart pill” in early testing. JAMA. 2018;320:965.
   Web of Science ®Google Scholar
• Hawkins T, Veikley W, St Claire RL, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr. 2005;39:406–411. doi:10.1097/01.qai.0000167155.44980.e8
   PubMed Web of Science ®Google Scholar
• Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29:384–390. doi:10.1089/aid.2012.0089
   PubMed Web of Science ®Google Scholar
• Anderson PL, Liu AY, Castillo-Mancilla JR, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018;62.
   Web of Science ®Google Scholar
• Yager J, Castillo-Mancilla J, Ibrahim ME, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following tenofovir alafenamide: the TAF-DBS study. J Acquir Immune Defic Syndr. 2020;84:323–330. doi:10.1097/QAI.0000000000002354
   Web of Science ®Google Scholar
• Saberi P, Ming K, Legnitto D, Neilands TB, Gandhi M, Johnson MO. Feasibility and acceptability of novel methods to estimate antiretroviral adherence: a longitudinal study. PLoS One. 2019;14:e0210791. doi:10.1371/journal.pone.0210791
   Web of Science ®Google Scholar
• Liu AY, Yang Q, Huang Y, et al. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014;9:e83736. doi:10.1371/journal.pone.0083736
   PubMed Web of Science ®Google Scholar
• Hickey MD, Salmen CR, Tessler RA, et al. Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr. 2014;66:311–315. doi:10.1097/QAI.0000000000000154
   Web of Science ®Google Scholar
• Gandhi M, Murnane PM, Bacchetti P, et al. Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. AIDS (London, England). 2017;31:2245–2251. doi:10.1097/QAD.0000000000001615
   Web of Science ®Google Scholar
• McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (London, England). 2016;387:53–60. doi:10.1016/S0140-6736(15)00056-2
   PubMed Web of Science ®Google Scholar
• Koenig HC, Mounzer K, Daughtridge GW, et al. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. HIV Med. 2017;18:412–418. doi:10.1111/hiv.12518
   PubMed Web of Science ®Google Scholar
• Moorthy GS, Lalley-Chareczko L, Koenig HC, Zuppa AF. Tenofovir urine assay to monitor adherence to HIV pre-exposure prophylaxis (PrEP). Curr Clin Pharmacol. 2019.
   Web of Science ®Google Scholar
• Lalley-Chareczko L, Hiserodt E, Moorthy G, Zuppa A, Mounzer K, Koenig H. Urine assay to measure tenofovir concentrations in patients taking tenofovir alafenamide. Front Pharmacol. 2020;11:286. doi:10.3389/fphar.2020.00286
   Web of Science ®Google Scholar
• Daughtridge G, Malone-Thomas S Use of a Urine Adherence Test Coupled with Adherence Intervention to Increase PrEP Adherence. Fast-Track Cities London. 2019.
   Google Scholar
• Daughtridge G, Hebel S, Hashim J, et al. Urine assay for tenofovir to monitor real-time adherence to tenofovir disoproxil fumarate and tenorovir alafenamide. HIV/AIDS J. 2020.
   Google Scholar
• Gandhi M, Wang G, King R, et al. Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings. AIDS (London, England). 2020;34:255–260. doi:10.1097/QAD.0000000000002395
   PubMed Web of Science ®Google Scholar
• Patient-friendly diagnostic tests that measure and improve adherence to medications; 2020. Available from: https://www.ursureinc.com/. Accessed January 21, 2021
   Google Scholar
• Drain PK, Kubiak RW, Siriprakaisil O, et al. Urine tenofovir concentrations correlate with plasma and relate to tenofovir disoproxil fumarate adherence: a randomized, directly observed pharmacokinetic trial (TARGET study). Clin Infect Dis. 2020;70:2143–2151. doi:10.1093/cid/ciz645
   Web of Science ®Google Scholar
• Kowalczyk Mullins TL, Braverman PK, Dorn LD, Kollar LM, Kahn JA. Adolescent preferences for human immunodeficiency virus testing methods and impact of rapid tests on receipt of results. J Adolesc Health. 2010;46:162–168. doi:10.1016/j.jadohealth.2009.06.015
   PubMed Web of Science ®Google Scholar
• Landovitz R. Tail-Phase Safety, Tolerability and Pharmacokinetics of Long-Acting Injectable Cabotegravir in HIV-Uninfected Individuals: HPTN 077 Final Results. Madrid: HIV Research for Prevention conference (HIVR4P 2018); 2018.
   Google Scholar
• Diagnostics Delivered; 2020. Available from: https://moleculartestinglabs.com/. Accessed January 21, 2021.
   Google Scholar
• Amico KR, Marcus JL, McMahan V, et al. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr. 2014;66:530–537. doi:10.1097/QAI.0000000000000216
   Web of Science ®Google Scholar
• Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17:2143–2155. doi:10.1007/s10461-013-0429-9
   PubMed Web of Science ®Google Scholar
• Haberer JE. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS. 2016;11:10–17. doi:10.1097/COH.0000000000000220
   PubMed Web of Science ®Google Scholar
• Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8:e80633.
   PubMed Web of Science ®Google Scholar
• CDC. Diagnoses of HIV infection in the United States and dependent areas. 2018–2019.
   Google Scholar